Next Article in Journal
Breast cancer and the environment: why research and preventive action are needed
Previous Article in Journal
Benefits, Issues, and Recommendations for Personalized Medicine in Oncology in Canada
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 20
Issue 5
10.3747/co.20.1546
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Nab-Paclitaxel Therapy

by
N.W.D. Lamond
*,
T. Younis
,
K. Purdy
and
M.S. Dorreen
Department of Medicine, Dalhousie University, Halifax, NS, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2013, 20(5), 484-487; https://doi.org/10.3747/co.20.1546
Submission received: 5 July 2013 / Revised: 8 August 2013 / Accepted: 6 September 2013 / Published: 1 October 2013

Abstract

Drug-induced lupus erythematosus (DILE) syndromes are documented complications of chemotherapeutic agents, including paclitaxel. Subacute cutaneous lupus erythematosus (SCLE) is a distinct DILE syndrome presenting with characteristic annular or papulosquamous skin lesions in a photosensitive distribution with associated high anti-SSA titres. Previously, DILE syndromes complicating paclitaxel therapy have been attributed to polyethoxylated castor oil (Kolliphor EL: BASF, Ludwigshafen, Germany), the biologic solvent included in the drug’s original formulation (Taxol: Bristol–Myers Squibb, Montreal, QC), rather than the parent chemotherapy molecule. Here, we report a characteristic case of drug-induced SCLE complicating treatment with nanoparticle albumin bound (nab)–paclitaxel (Abraxane: Celgene, Summit, NJ, U.S.A.), a solvent-free taxane formulation. The pertinent English-language literature is also discussed. This case report is the first to link solvent-free paclitaxel with SCLE, and it suggests that the parent molecule is responsible for the reaction.
Keywords: nanoparticle albumin-bound paclitaxel; nab-paclitaxel; subacute cutaneous lupus erythematosus; cutaneous drug reactions nanoparticle albumin-bound paclitaxel; nab-paclitaxel; subacute cutaneous lupus erythematosus; cutaneous drug reactions

Share and Cite

MDPI and ACS Style

Lamond, N.W.D.; Younis, T.; Purdy, K.; Dorreen, M.S. Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Nab-Paclitaxel Therapy. Curr. Oncol. 2013, 20, 484-487. https://doi.org/10.3747/co.20.1546

AMA Style

Lamond NWD, Younis T, Purdy K, Dorreen MS. Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Nab-Paclitaxel Therapy. Current Oncology. 2013; 20(5):484-487. https://doi.org/10.3747/co.20.1546

Chicago/Turabian Style

Lamond, N.W.D., T. Younis, K. Purdy, and M.S. Dorreen. 2013. "Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Nab-Paclitaxel Therapy" Current Oncology 20, no. 5: 484-487. https://doi.org/10.3747/co.20.1546

APA Style

Lamond, N. W. D., Younis, T., Purdy, K., & Dorreen, M. S. (2013). Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Nab-Paclitaxel Therapy. Current Oncology, 20(5), 484-487. https://doi.org/10.3747/co.20.1546

Article Metrics

Back to TopTop